Changes in Beneficial Ownership · 4
Apnimed, Inc.
APMDNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-07-30
- Issuer
- Apnimed, Inc.
- Issuer CIK
- 0001745648
- Trading symbol
- APMD
Reporting owner 1
- Name
- SEKHRI PAUL J
- Reporting owner CIK
- 0001264519
- Relationship
- Director
- Address
- APNIMED, INC., 39 JOHN F. KENNEDY STREET, 4TH FLOOR, CAMBRIDGE, MA, 02138
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-08-03 | P · Form 4 | 12,500 | A | 16.00 | 12,500 | D |
Table key
- P · Form 4
- Purchase on the market or privately
- A
- Acquired
- D
- Direct
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | 8.15 | 2026-08-03 | D · Form 4[F1] | 169,468 | D | 0 | [F2] | 2036-05-28 | Class A Common Stock | 169,468 | 0 | D |
| Stock Option (Right to Buy) | 8.15 | 2026-08-03 | A · Form 4[F1] | 169,468 | A | 0 | [F2] | 2036-05-28 | Common Stock | 169,468 | 169,468 | D |
| Stock Option (Right to Buy) | 16.00 | 2026-07-30 | A · Form 4 | 155,558 | A | 0 | [F2] | 2036-07-29 | Class A Common Stock | 155,558 | 155,558 | D |
| Stock Option (Right to Buy) | 16.00 | 2026-08-03 | D · Form 4[F1] | 155,558 | A | 0 | [F2] | 2036-07-29 | Class A Common Stock | 155,558 | 0 | D |
| Stock Option (Right to Buy) | 16.00 | 2026-08-03 | A · Form 4[F1] | 155,558 | A | 0 | [F2] | 2036-07-29 | Common Stock | 155,558 | 155,558 | D |
| Stock Option (Right to Buy) | 16.00 | 2026-07-30 | A · Form 4 | 22,238 | A | 0 | [F3] | 2036-07-29 | Class A Common Stock | 22,238 | 22,238 | D |
| Stock Option (Right to Buy) | 16.00 | 2026-08-03 | D · Form 4[F1] | 22,238 | D | 0 | [F3] | 2036-07-29 | Class A Common Stock | 22,238 | 0 | D |
| Stock Option (Right to Buy) | 16.00 | 2026-08-03 | A · Form 4[F1] | 22,238 | A | 0 | [F3] | 2036-07-29 | Common Stock | 22,238 | 22,238 | D |
Table key
- D · Form 4
- Disposition to the issuer under Rule 16b-3(e)
- D
- Direct
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
Footnotes
- F1
- Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock.↩ 1↩ 2↩ 3↩ 4↩ 5↩ 6
- F2
- One-third of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after June 1, 2026, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 24 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.↩ 1↩ 2↩ 3↩ 4↩ 5
Signature 1
- Signed
- /s/Kevin R. Lind, Attorney-in-Fact
- Date
- 2026-08-03
Company context
We are a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases. Our sole clinical product candidate, AD109 (Oxnimbi), is an investigational, fixed-dose, anti-apneic neuromuscular modulator, combining a novel anti-muscarinic and a selective norepinephrine reuptake inhibitor (NRI) for the treatment of obstructive sleep apnea (OSA). Oxnimbi is designed to target the neuromuscular defect of OSA by improving upper airway muscle activity to help maintain airway patency and prevent airway collapse during sleep. Based on results from two registrational trials, we submitted a New Drug Application (NDA) for Oxnimbi to the U.S. Food and Drug Administration (FDA) in April 2026, which was accepted for review by the FDA in July 2026. The registrational trials were Phase 3, randomized, double-blind, placebo-controlled, parallel-arm trials in adults with mild to severe OSA, LunAIRo and SynAIRgy, which together enrolled approximately 1,300 patients and represent one of the largest and most diverse cohorts ever studied in an OSA pharmacologic trial. LunAIRo was conducted in the United States and SynAIRgy was conducted in the United States and Canada. All previous trials of Oxnimbi were conducted in the United States. In this prospectus, we also refer to AD109 by its proposed future brand name, “Oxnimbi.” This brand name was conditionally approved by the F